Lawyers

• Wyeth Whistleblowers Share $98.1 Million Out of $784.6 Million Recovery From Pfizer

  Pfizer Inc. has agreed paying $784.6 million for the fraudulence committed by its Wyeth unit, according to a Justice Department announcement on Wednesday. Though the fraud has been committed three years before acquiring Wyeth, Pfizer intends to resolve past cases. However, the settlement brings $98.1 million from the recovered amount for the two whistleblowers who have unearthed the fraud and brought Wyeth to book.

• Pfizer Lawsuit Over Celebrex, Bextra Safety Sent Back to Lower Court

  Pfizer is facing a lawsuit that had been revived 12 years after. The New York-based company is being sued by shareholders of the company, who claimed that they were not informed of the cardiovascular risks of Celebrex and Bextra. The shareholders suffered substantial amount of losses.

• India Pfizer stops cough syrup production

  The Indian Government has ordered Pfizer India for an immediate ban of a cough syrup, Corex, a prescription drug that have been in the market for more than 30 years.

• Pfizer unit to pay $784.6 million in Medicaid refund settlement

  Pfizer's Wyeth unit has already agreed to pay $784.6 million. This will allegedly settle claims that the company's calculation of the Medicaid rebates for Protonix violated the Federal Civil False Claims Act and other laws.

• US Supreme Court penalizes pharmaceutical companies against FDA-approved drug labeling

  While the United States Supreme Court approved a petition to clear up misunderstanding over the drug-labeling mandates by the FDA, both the pharmaceutical companies and the public would gain benefit should they re-examine the rules set by the drug-regulating agency.

• Pfizer wins first U.S. trial over Zoloft birth-defect risk

  Pfizer Inc scored a key victory Friday when it was cleared of liability in the first U.S. trial involving claims that its antidepressant Zoloft can cause birth defects in children born to women who take the drug while pregnant.

• Ex-Ameriprise broker pleads guilty after SEC insider trading case

  A former Ameriprise Financial Inc stockbroker previously accused by U.S. securities regulators of engaging in insider trading ahead of a 2010 merger by Pfizer Inc has pleaded guilty to conspiracy to commit securities fraud.

• FDA panel votes to keep severe warning on Pfizer anti-smoking drug

  Pfizer Inc failed to convince the U.S. Food and Drug Administration to remove a black box warning on its controversial quit-smoking drug Chantix, with an advisory panel to the agency voting against the removal on Thursday.

• Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor

  Pfizer Inc and India's Ranbaxy Laboratories Ltd on Friday won dismissal of a U.S. antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the best-selling cholesterol drug Lipitor.

• Pfizer sues rival to block sale of cheaper Viagra

  Pfizer Inc has filed an injunction to stop the production, marketing, sale and distribution of Ahmedabad, India-based Torrent Pharmaceuticals Ltd's generic version of Viagra, Bloomberg reported.